Key result
High serum Angiopoietin 2 levels were associated with shorter recurrence-free survival in patients with hepatocellular carcinoma treated with curative ablation.
Why the study?
Although Angiopoietin 2 plays a central role in tumor angiogenesis in hepatocellular carcinoma, its role as a serum biomarker remained unclear.
Does serum Ang2 act as a diagnostic and prognostic biomarker in patients with hepatocellular carcinoma?
Observational (n=393)
No
Does serum Ang2 act as a diagnostic and prognostic biomarker in patients with hepatocellular carcinoma?
Serum Ang2 is a potential novel biomarker for both the diagnosis of hepatocellular carcinoma and the prediction of recurrence-free survival after curative ablation therapy.
This is the authors' abstract. We don't add key points for this paper.
Hepatocellular carcinoma (HCC) is typically accompanied by abundant arterial blood flow. Although angiogenic growth factors such as Angiopoietin 2 (Ang2) play a central role in tumor angiogenesis in HCC, the role of serum Ang2 as a biomarker in HCC remains unclear. In this study, we aimed to investigate the potential of Ang2 as a diagnostic and prognostic biomarker in HCC using a sandwich enzyme-linked immunosorbent assay (ELISA). The median Ang2 levels in controls (n=20), chronic liver disease patients (n=98), and HCC patients (n=275) were 1.58, 2.33, and 3.53 ng/mL, respectively. The optimal cut-off value of Ang2 was determined as 3.5 ng/mL by receiver operating curve analysis. The sensitivity, specificity, and accuracy of Ang2 for HCC detection were 50.9, 83.7, and 59.5%, respectively. Spearman's rank correlation coefficient analysis demonstrated only a weak correlation between Ang2 serum levels and alpha-fetoprotein (AFP) or des-gamma-carboxy prothrombin (DCP) serum levels. The diagnostic value of Ang2 was comparable to those of other existing markers. In addition, 24 out of 73 patients with normal AFP and DCP levels (32.9%) demonstrated abnormally high Ang2 levels (3.5 ng/mL). Although no significant difference in overall survival was found between Ang2 high and Ang2 low patients with curative ablation therapy, recurrence-free survival (RFS) in Ang2 high patients was observed to be significantly shorter than those in Ang2 low patients. Multivariate analysis demonstrated that high serum Ang2 levels (3.5 ng/mL) and the presence of multiple tumors were poor prognostic factors. In conclusion, our findings indicate that serum Ang2 is a potential novel biomarker for both diagnosis and prognosis in HCC.
Answers are grounded in this paper and cite their sources.
Serum Ang2 may complement AFP/DCP for HCC detection; leaves open prospective validation before prognostic adoption.
No takes yet. Share an insight, caveat, or question.
Ao et al. (2021) conducted an observational in Hepatocellular carcinoma (n=393). High serum Angiopoietin 2 (≥3.5 ng/mL) vs. Low serum Angiopoietin 2 (<3.5 ng/mL) was evaluated on Recurrence-free survival (median months) (HR 1.633, 95% CI 1.032-2.754, p=0.041). High serum Angiopoietin 2 levels were associated with shorter recurrence-free survival in patients with hepatocellular carcinoma treated with curative ablation.
Synapse has enriched 10 related papers. Consider them for comparative context: